Literature DB >> 14697673

Constitutive EGFR signaling confers a motile phenotype to neural stem cells.

John A Boockvar1, Dmitri Kapitonov, Gurpreet Kapoor, Joost Schouten, George J Counelis, Oliver Bogler, Evan Y Snyder, Tracy K McIntosh, Donald M O'Rourke.   

Abstract

The epidermal growth factor receptor (EGFR) has been shown to play an important role in brain development, including stem and precursor cell survival, proliferation, differentiation, and migration. To further examine the temporal and spatial requirements of erbB signals in uncommitted neural stem cells (NSCs), we expressed the ligand-independent EGF receptor, EGFRvIII, in C17.2 NSCs. These NSCs are known to migrate and to evince a tropic response to neurodegenerative environments in vivo but for which an underlying mechanism remains unclear. We show that enhanced erbB signaling via constitutive kinase activity of EGFRvIII in NSCs sustains an immature phenotype and enhances NSC migration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14697673     DOI: 10.1016/j.mcn.2003.09.011

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  59 in total

1.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Authors:  John H Sampson; Amy B Heimberger; Gary E Archer; Kenneth D Aldape; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert J Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.

Authors:  Patrick C Gedeon; Bryan D Choi; John H Sampson; Darell D Bigner
Journal:  Drugs Future       Date:  2013-03       Impact factor: 0.148

3.  The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.

Authors:  Yi Zhan; George J Counelis; Donald M O'Rourke
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

4.  Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.

Authors:  Fanny Burel-Vandenbos; Laurent Turchi; Maxime Benchetrit; Eric Fontas; Zoe Pedeutour; Valérie Rigau; Fabien Almairac; Damien Ambrosetti; Jean-François Michiels; Thierry Virolle
Journal:  Neuro Oncol       Date:  2013-08-09       Impact factor: 12.300

Review 5.  Receptor tyrosine kinase (RTK) signalling in the control of neural stem and progenitor cell (NSPC) development.

Authors:  Alexander Annenkov
Journal:  Mol Neurobiol       Date:  2013-08-28       Impact factor: 5.590

Review 6.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.

Authors:  Marie-Thérése Stockhausen; Karina Kristoffersen; Louise Stobbe; Hans Skovgaard Poulsen
Journal:  Cancer Biol Ther       Date:  2013-11-01       Impact factor: 4.742

8.  The Potentials and Pitfalls of Using Adult Stem Cells in Cancer Treatment.

Authors:  Mrinal K Das; Taral R Lunavat; Hrvoje Miletic; Jubayer A Hossain
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.

Authors:  Li Li; Amalia Dutra; Evgenia Pak; Joseph E Labrie; Rachel M Gerstein; Pier Paolo Pandolfi; Larry D Recht; Alonzo H Ross
Journal:  Neuro Oncol       Date:  2008-09-23       Impact factor: 12.300

Review 10.  Applications of neural and mesenchymal stem cells in the treatment of gliomas.

Authors:  Thomas Kosztowski; Hasan A Zaidi; Alfredo Quiñones-Hinojosa
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.